Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:focusesOn |
oncolytic immunotherapies
|
| gptkbp:foundedYear |
2015
|
| gptkbp:founder |
gptkb:Robert_Coffin
|
| gptkbp:headquartersLocation |
gptkb:Woburn,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Replimune
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableEmployee |
gptkb:Robert_Coffin
Sushil Patel |
| gptkbp:products |
gptkb:RP1
gptkb:RP2 gptkb:RP3 |
| gptkbp:publiclyTraded |
true
|
| gptkbp:specializesIn |
oncolytic virus therapies
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
REPL
|
| gptkbp:website |
https://www.replimune.com/
|
| gptkbp:bfsParent |
gptkb:Atlas_Venture
gptkb:David_Grayzel |
| gptkbp:bfsLayer |
6
|